OncoCyte Corp reports results for the quarter ended in December - Earnings Summary

Insight Molecular Diagnostics

12/04/2024 14:31

* OncoCyte Corp  OCX.OQ  reported a quarterly adjusted loss
of
$2.12​​ per share for the quarter ended in December, higher than
the same quarter last year, when the company reported EPS of
$-8.00.  The mean expectation of four analysts for the quarter
was for a loss of $1.14 per share. Wall Street expected
results to range from $-1.57 to -70 cents per share.
    * Revenue fell 72% to $314.00 thousand from a year ago;
analysts
expected $316.67 thousand. 
    * OncoCyte Corp's reported EPS for the quarter was a loss of
$2.12​.
    * The company reported a quarterly loss of $16.2 million.
    * OncoCyte Corp shares had risen by 1.2% this quarter and
gained 18.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for OncoCyte Corp is
$3.80 
This summary was machine generated from LSEG data April 12 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -1.14          -2.12          Missed
 Sep. 30 2023      -1.01          -0.81          Beat
 Jun. 30 2023      -1.30          -1.07          Beat
 Mar. 31 2023      -1.84          0.40           Beat